BTK Inhibitor Shows Potential in Early Phase Trial for MS
August 15th 2018A phase 1 trial evaluating the safety and tolerability of PRN2246, a Bruton's tyrosine kinase (BTK) inhibitor, found the drug having no serious medication-related adverse events in healthy volunteers while also being able to reach the brain.
Read More